Skip to main content
logo
Mersana Therapeutics, Inc. (MRSN)
Jan 6, 2026 - MRSN was delisted (reason: acquired by DAWN)
29.08
+0.04 (0.14%)
Inactive · Last trade price on Jan 5, 2026

Mersana Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingSep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
33.1840.536.8626.580.040.83
Revenue Growth
-4.76%9.88%38.65%61716.28%-94.81%-98.03%
Gross Profit
-35.85-32.52-111.41-146.8-131.97-66.21
Operating Income
-67.38-73.34-170.96-203.77-168.86-88.11
Net Income
-70.08-69.19-171.67-204.21-170.06-88.05
Earnings Per Share
-14.09-14.12-36.96-54.51-60.24-35.80
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingSep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Cash & Investments
56.39134.62209.08280.71177.95255.09
Total Debt
2.2928.6533.8336.7538.8616.84
Net Cash (Debt)
54.1105.97175.25243.97139.08238.26
Net Cash Growth
-56.25%-39.53%-28.17%75.41%-41.62%159.92%
Net Cash Per Share
10.8721.6237.7365.1249.2696.87

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingSep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Operating Cash Flow
-74.37-82.34-168.88-49.36-139.99-74.7
Capital Expenditures
--0.13-2.17-2.2-0.65-0.47
Free Cash Flow
-74.37-82.47-171.05-51.56-140.64-75.17
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingSep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Gross Margin
-108.04%-80.31%----
Operating Margin
-203.06%-181.09%-463.86%-766.59%-392693.02%-10641.30%
Pretax Margin
-211.21%-169.82%-465.80%-768.26%-395488.37%-10633.45%
Profit Margin
-211.22%-170.86%-465.80%-768.26%-395488.37%-10633.45%
FCF Margin
-224.14%-203.65%-464.12%-193.97%-327060.47%-9078.38%

Valuation
Chart
Fiscal YearCurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingAug '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
PS Ratio
4.364.367.5922.0010402.132201.35